PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab

Chanukya Dahagam; Aditya Goud; Abdelhai Abdelqader; Aditya Hendrani; Matthew J. Feinstein; Arman Qamar; Parag H. Joshi; Kristopher J. Swiger; Kathleen Byrne; Renato Quispe; Steven R. Jones; Roger S. Blumenthal; Seth S. Martin

doi:10.2217/fca.15.88

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab

Chanukya Dahagam, Aditya Goud, Abdelhai Abdelqader, Aditya Hendrani, Matthew J. Feinstein, Arman Qamar, Parag H. Joshi, Kristopher J. Swiger, Kathleen Byrne, Renato Quispe, Steven R. Jones, Roger S. Blumenthal, Seth S. Martin^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

In this review, we examine alirocumab (Praluent®), a monoclonal antibody to PCSK9 and its role in reducing LDL-C levels. By comparing the results of various studies and trials we discuss the efficacy and safety of alirocumab. We aim to guide clinicians of the role of alirocumab in clinical practice. Overall, PCSK9 inhibitors are promising new agents in further reducing LDL-C levels in addition to diet and maximally tolerated statin therapy. Long-term outcome studies are currently ongoing and will further delineate the role of PCSK9 inhibitors.

Original language	English (US)
Pages (from-to)	149-157
Number of pages	9
Journal	Future Cardiology
Volume	12
Issue number	2
DOIs	https://doi.org/10.2217/fca.15.88
State	Published - Mar 2016

Keywords

LDL
PCSK9 inhibitors
alirocumab
evolocumab
monoclonal antibodies
statin intolerance

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Molecular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fca.15.88

Cite this

@article{a1d4782612a74c4a8d8251131a2873f1,

title = "PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab",

abstract = "In this review, we examine alirocumab (Praluent{\textregistered}), a monoclonal antibody to PCSK9 and its role in reducing LDL-C levels. By comparing the results of various studies and trials we discuss the efficacy and safety of alirocumab. We aim to guide clinicians of the role of alirocumab in clinical practice. Overall, PCSK9 inhibitors are promising new agents in further reducing LDL-C levels in addition to diet and maximally tolerated statin therapy. Long-term outcome studies are currently ongoing and will further delineate the role of PCSK9 inhibitors.",

keywords = "LDL, PCSK9 inhibitors, alirocumab, evolocumab, monoclonal antibodies, statin intolerance",

author = "Chanukya Dahagam and Aditya Goud and Abdelhai Abdelqader and Aditya Hendrani and Feinstein, {Matthew J.} and Arman Qamar and Joshi, {Parag H.} and Swiger, {Kristopher J.} and Kathleen Byrne and Renato Quispe and Jones, {Steven R.} and Blumenthal, {Roger S.} and Martin, {Seth S.}",

note = "Publisher Copyright: {\textcopyright} 2016 Future Medicine Ltd.",

year = "2016",

month = mar,

doi = "10.2217/fca.15.88",

language = "English (US)",

volume = "12",

pages = "149--157",

journal = "Future Cardiology",

issn = "1479-6678",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels

T2 - Alirocumab

AU - Dahagam, Chanukya

AU - Goud, Aditya

AU - Abdelqader, Abdelhai

AU - Hendrani, Aditya

AU - Feinstein, Matthew J.

AU - Qamar, Arman

AU - Joshi, Parag H.

AU - Swiger, Kristopher J.

AU - Byrne, Kathleen

AU - Quispe, Renato

AU - Jones, Steven R.

AU - Blumenthal, Roger S.

AU - Martin, Seth S.

PY - 2016/3

Y1 - 2016/3

N2 - In this review, we examine alirocumab (Praluent®), a monoclonal antibody to PCSK9 and its role in reducing LDL-C levels. By comparing the results of various studies and trials we discuss the efficacy and safety of alirocumab. We aim to guide clinicians of the role of alirocumab in clinical practice. Overall, PCSK9 inhibitors are promising new agents in further reducing LDL-C levels in addition to diet and maximally tolerated statin therapy. Long-term outcome studies are currently ongoing and will further delineate the role of PCSK9 inhibitors.

AB - In this review, we examine alirocumab (Praluent®), a monoclonal antibody to PCSK9 and its role in reducing LDL-C levels. By comparing the results of various studies and trials we discuss the efficacy and safety of alirocumab. We aim to guide clinicians of the role of alirocumab in clinical practice. Overall, PCSK9 inhibitors are promising new agents in further reducing LDL-C levels in addition to diet and maximally tolerated statin therapy. Long-term outcome studies are currently ongoing and will further delineate the role of PCSK9 inhibitors.

KW - LDL

KW - PCSK9 inhibitors

KW - alirocumab

KW - evolocumab

KW - monoclonal antibodies

KW - statin intolerance

UR - http://www.scopus.com/inward/record.url?scp=84959923543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959923543&partnerID=8YFLogxK

U2 - 10.2217/fca.15.88

DO - 10.2217/fca.15.88

M3 - Review article

C2 - 26911578

AN - SCOPUS:84959923543

SN - 1479-6678

VL - 12

SP - 149

EP - 157

JO - Future Cardiology

JF - Future Cardiology

IS - 2

ER -

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this